Royalty Report: Drugs, Pharmaceuticals, Wound Care – Collection: 26884


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Wound Care
  • Therapeutic
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26884

License Grant
The Licensor entered into a collaboration and license agreement with the Licensee who is a U.S. subsidiary of a Japanese company for the co-development and commercialization of MBI 226.  

MBI 226 is in a Phase III clinical trial in the United States for the prevention of central venous catheter-related bloodstream infections.  Granted are exclusive rights to market and sell the product in the US, Canada and Mexico.

Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 6538

License Grant
The Licensor entered into a partnership with the Licensee, to co-develop and co-market linaclotide in the U.S.  Under the terms of the collaboration Agreement, the Licensor and the Licensee are jointly and equally funding the development and commercialization of linaclotide in the U.S., with equal share of any profits. The Licensee also has exclusive rights to develop and commercialize linaclotide in Canada and Mexico. The collaboration Agreement will continue in full force and effect with respect to each of the U.S., Canada and Mexico as long as the parties are developing or commercializing a product under the Agreement.
License Property
Linaclotide is a first-in-class compound currently in confirmatory Phase 3 clinical trials evaluating its safety and efficacy for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 211926

License Grant
The Canadian Licensor grants an exclusive, royalty-bearing license under the Licensor Technology to use, market, advertise, promote, distribute, offer for sale, sell, make, manufacture, have manufactured, export and import, and develop the Product in the Territory for use in the Field with the right to sublicense.
License Property
The licensed property is patents and know-how related to the compound.  The compound is omiganan pentahydrochloride.

Omiganan pentahydrochloride (formerly MBI 226) is a novel topical cationic peptide analog of indolicidin that was originally purified from the cytoplasmic granules of bovine neutrophils.  A topical 1% gel preparation of omiganan is currently in phase III clinical trials for the prevention of catheter-related bloodstream infections

The Product means any and all pharmaceutical formulations containing any and all concentrations, sizes of volume, configurations and combinations of the Compound.

Field of Use
Field means the topical administration to a burn site or a surgical wound site for the treatment or prevention in humans or burn-related or surgery-related infections, and topical administration to a device or a site around the device for the treatment or prevention in humans of device-related infections, including LCSI or  local catheter site infection and CRBSI or catheter related blood stream infection.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.